Shufro Rose & Co’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

Shufro Rose & Co’s Portfolio ARLZ Stock Details ARLZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-20,987	Closed	-$7K	–	314
2018 Q2	$7K	Hold	20,987	–	–	﹤0.01%	298
2018 Q1	$31K	Buy	20,987 +3,000	+17%	+$5.24K	﹤0.01%	301
2017 Q4	$26K	Hold	17,987	–	–	﹤0.01%	287
2017 Q3	$41K	Hold	17,987	–	–	﹤0.01%	285
2017 Q2	$24K	Sell	17,987 -5,000	-22%	-$7.22K	﹤0.01%	266
2017 Q1	$49K	Buy	22,987 +1,500	+7%	+$5.64K	0.01%	267
2016 Q4	$95K	Hold	21,487	–	–	0.01%	256
2016 Q3	$104K	Buy	21,487 +5,000	+30%	+$22.8K	0.01%	256
2016 Q2	$54K	Hold	16,487	–	–	0.01%	261
2016 Q1	$59K	Buy	+16,487	New	+$85K	0.01%	264

Other funds holding ARLZ

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Shufro Rose & Co's ARLZ Position: Q3 2018 in Review

Shufro Rose & Co sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q3 2018, closing a stake of 20,987 shares — an estimated $7K sold.

Shufro Rose & Co first reported a position in ARLZ in Q1 2016 and held it in 10 quarters. The position peaked at $104K in Q3 2016. 4 funds tracked by Wall St. Rank hold ARLZ as of Q3 2018.

Shufro Rose & Co reported no remaining Aralez Pharmaceuticals Inc. position as of Q3 2018 after selling out during the quarter.
Shufro Rose & Co sold 20,987 Aralez Pharmaceuticals Inc. shares in Q3 2018, an estimated $7K.
Shufro Rose & Co first reported a position in Aralez Pharmaceuticals Inc. in Q1 2016 and held it in 10 quarters.
Shufro Rose & Co's Aralez Pharmaceuticals Inc. position peaked at $104K in Q3 2016.
4 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q3 2018.

Based on Shufro Rose & Co's 13F filing for Q3 2018, filed 26 Oct 2018.